ADVFN Logo ADVFN

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Inozyme Pharma Inc

Inozyme Pharma Inc (INZY)

1.995
-0.805
(-28.75%)
Cerrado 11 Enero 3:00PM
2.08
0.085
(4.26%)
Fuera de horario: 6:18PM
Gráfico avanzado

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
2.08
Postura de Compra
2.01
Postura de Venta
2.15
Volume Operado de la Acción
2,238,733
1.97 Rango del Día 2.7443
1.98 Rango de 52 semanas 7.795
Capitalización de Mercado [m]
Precio Anterior
2.80
Precio de Apertura
2.71
Última hora de negociación
Volumen financiero
US$ 4,918,429
Precio Promedio Ponderado
2.197
Volumen promedio (3 m)
557,546
Acciones en circulación
64,240,198
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-1.81
Beneficio por acción (BPA)
-1.11
turnover
-
Beneficio neto
-71.17M

Acerca de Inozyme Pharma Inc

Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 ... Inozyme Pharma Inc is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies. Its product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Inozyme Pharma Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker INZY. The last closing price for Inozyme Pharma was US$2.80. Over the last year, Inozyme Pharma shares have traded in a share price range of US$ 1.98 to US$ 7.795.

Inozyme Pharma currently has 64,240,198 shares in issue. The market capitalisation of Inozyme Pharma is US$179.87 million. Inozyme Pharma has a price to earnings ratio (PE ratio) of -1.81.

INZY Últimas noticias

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of disease, including survival, heart function, and...

Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...

Inozyme Pharma to Present at Upcoming Investor Conferences

BOSTON, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“the Company” or “Inozyme”), a clinical-stage biopharmaceutical company developing innovative therapeutics for rare...

Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights

- Interim data from ENERGY 1, a Phase 1b trial of INZ-701 in infants with ENPP1 Deficiency, on track for fourth quarter of 2024 – - Topline data from ENERGY 3, a pivotal trial of INZ-701 in...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.77-27.01754385962.853.181.985363322.91386622CS
4-0.9-30.20134228192.983.281.985069632.92471701CS
12-3.1-59.84555984565.185.591.985575463.11831291CS
26-2.56-55.17241379314.646.241.983901533.88693895CS
52-2.57-55.26881720434.657.7951.984543404.7569166CS
156-4.36-67.7018633546.447.980.9914797554.24205713CS
260-15.85-88.399330730617.9331.64990.9913444375.14465962CS

INZY - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Inozyme Pharma?
El precio actual de las acciones de Inozyme Pharma es US$ 2.08
¿Cuántas acciones de Inozyme Pharma están en circulación?
Inozyme Pharma tiene 64,240,198 acciones en circulación
¿Cuál es la capitalización de mercado de Inozyme Pharma?
La capitalización de mercado de Inozyme Pharma es USD 179.87M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Inozyme Pharma?
Inozyme Pharma ha negociado en un rango de US$ 1.98 a US$ 7.795 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Inozyme Pharma?
El ratio precio/beneficio de Inozyme Pharma es -1.81
¿Cuál es la moneda de reporte de Inozyme Pharma?
Inozyme Pharma presenta sus resultados financieros en USD
¿Cuál es el último beneficio anual de Inozyme Pharma?
El último beneficio anual de Inozyme Pharma es USD -71.17M
¿Cuál es la dirección registrada de Inozyme Pharma?
La dirección registrada de Inozyme Pharma es CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
¿Cuál es la dirección del sitio web de Inozyme Pharma?
La dirección del sitio web de Inozyme Pharma es www.inozyme.com
¿En qué sector industrial opera Inozyme Pharma?
Inozyme Pharma opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
VRMEVerifyMe Inc
US$ 2.57
(52.98%)
57.83M
WKEYWISeKey International Holdings AG
US$ 10.041
(52.83%)
6.72M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
INTZIntrusion Inc
US$ 2.8888
(44.44%)
40.61M
IGMSIGM Biosciences Inc
US$ 2.095
(-66.21%)
5.81M
CDTGCDT Environmental Technology Investment Holdings Ltd
US$ 1.87
(-51.30%)
2.28M
MODVModivCare Inc
US$ 6.51
(-47.88%)
2.73M
AIFUAIX Inc
US$ 0.420501
(-47.76%)
7.85M
MRSNMersana Therapeutics Inc
US$ 0.691
(-46.85%)
58.44M
CDTConduit Pharmaceuticals Inc
US$ 0.1214
(48.05%)
1.17B
NVDANVIDIA Corporation
US$ 135.91
(-3.00%)
207.53M
RGTIRigetti Computing Inc
US$ 8.9299
(-11.06%)
178.82M
VMARVision Marine Technologies Inc
US$ 2.14
(40.79%)
175.57M
DATSDatChat Inc
US$ 4.8105
(49.86%)
158.65M

INZY Finanzas

Finanzas

INZY Discussion

Ver más
tj9938 tj9938 2 meses hace
Taking a beating this week. 
👍️0
Monksdream Monksdream 4 meses hace
INZY under $6
👍️0
AJ Freely AJ Freely 1 año hace
$INZY - 👆Up 7% Pre-Market/ Current Price $5.12
Pivotal bioVenture Partners Fund I, L.P purchases
835k shares equal to $4m investment
👍️0
Monksdream Monksdream 1 año hace
INZY new 52 week high
👍️0
INFINITI INFINITI 2 años hace
Loading
👍️0
Jess070283 Jess070283 2 años hace
Have a feeling this about to squeeze into a halt soon…..
👍️0
tj9938 tj9938 2 años hace
Great week so far. Gotta keep it movin.
👍️0
tj9938 tj9938 2 años hace
Quietest board out there
👍️0
ErnieBilco ErnieBilco 3 años hace
Grabbed a starter here today
👍️0
crudeoil24 crudeoil24 3 años hace
INZ-701 is currently in a Phase 1/2 clinical trial for ENPP1 Deficiency. Inozyme Pharma was founded in 2017 by Joseph Schlessinger, Ph.D., Demetrios Braddock, M.D., Ph.D., and Axel Bolte, MSc, MBA, with technology developed by Dr. Braddock and licensed from Yale University. For more information, please visit www.inozyme.com
👍️0
crudeoil24 crudeoil24 3 años hace
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. It is also focused on developing a therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-binding cassette sub-family C member 6 (ABCC6) deficiencies. The Company's lead product candidate, INZ-701, is a soluble, recombinant, or genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ENPP1 and ABCC6 deficiencies.
👍️0
crudeoil24 crudeoil24 3 años hace
Inozyme Pharma 13G Filing From Deep Track Capital Shows New 8.11% Stake

(i) Deep Track Capital, LP

(ii) Deep Track Biotechnology Master Fund, Ltd.

(iii) David Kroin

INZY
👍️0
tw0122 tw0122 3 años hace
I like the BioXc chart looks better. Thanks for all the good insight.
👍️0
crudeoil24 crudeoil24 3 años hace
The offering is expected to close on or about April 19, 2022
👍️0
tw0122 tw0122 3 años hace
This analyst know about the offering?
Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of abnormal mineralization, today announced the pricing of an underwritten offering of 16,276,987 shares of its common stock at a price of $3.69 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 3,523,013 shares of common stock at a price of $3.6899 per pre-funded warrant, for aggregate gross proceeds of approximately $73 million, before deducting underwriting discounts and commissions and other offering expenses. The purchase price per share of each pre-funded warrant represents the per share public offering price for the common stock, minus the $0.0001 per share exercise price of such pre-funded warrant. All of the securities are being offered by Inozyme. The offering is expected to close on or about April 19, 2022, subject to customary closing conditions.
👍️0
crudeoil24 crudeoil24 3 años hace
PT > 33.00
👍️0
crudeoil24 crudeoil24 3 años hace
H.C. Wainwright analyst Edward White maintained a Buy rating on Inozyme Pharma (INZY – Research Report) yesterday and set a price target of $33.00. The company's shares closed last Tuesday at $3.89, close to its 52-week low of $3.54. According to TipRanks.com, White is ranked 0 out of 5 stars with an average return of -19.5% and a 25.5% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics. Inozyme Pharma has an analyst consensus of Strong Buy, with a price target consensus of $30.00, a 541.0% upside from current levels.
👍️0

Su Consulta Reciente

Delayed Upgrade Clock